9,12-Octadecadienoic acid (9Z,12Z)-, dimer

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 9,12-Octadecadienoic acid (9Z,12Z)-, dimer
• 英文别名: (9Z,12Z)-octadeca-9,12-dienoic acid
• 化学式: C36H64O4
• 分子量: 560.9
• InChiKey: VJZWIFWPGRIJSN-XRHABHTOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.77
• 重原子数：
  40
• 可旋转键数：
  28
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS
  申请人：HANSEN Christian

  公开号：US20110269675A1

  公开（公告）日：2011-11-03

  A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular hone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

  一种用于治疗和/或预防哺乳动物中的骨坏死性骨病，例如特发性或继发性骨坏死、缺血性骨坏死、糖皮质激素诱导的骨缺血/骨坏死、Legg-Calve-Perthes病和股骨头坏死的方法，包括向哺乳动物投予有效剂量的含锶化合物（a）。一种用于治疗和/或预防骨坏死性骨病的方法，例如特发性或继发性骨坏死、缺血性骨坏死、糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死，该方法适用于要或正在接受已知或疑似诱导骨细胞凋亡和/或坏死的治疗剂（b）的哺乳动物，包括同时投予含锶化合物（a）和（b）。
• HYDROXY- AND ALDEHYDE FUNCTIONAL COMPOUNDS
  申请人：Meier Michael A.R.

  公开号：US20110198535A1

  公开（公告）日：2011-08-18

  The invention relates to a method for producing a mixture containing hydroxy- and aldehyde functional compounds by a cross-metathesis reaction of at least one at least monounsaturated fatty acid or at least one at least monounsaturated fatty acid derivative with an olefinic compound having at least one hydroxy group and at least one C—C double bond, in the presence of a metathesis catalyst at a maximum temperature of 180° C.

  本发明涉及一种方法，通过交叉烯烃反应，在至多180°C的最高温度下，将至少一种至少单不饱和脂肪酸或至少一种至少单不饱和脂肪酸衍生物与至少一种具有至少一个羟基和至少一个C-C双键的烯烃化合物在存在烯烃交换催化剂的情况下反应，以产生含有羟基和醛基官能团的混合物。
• METHOD FOR PRODUCING ALDEHYDE FUNCTIONAL COMPOUNDS
  申请人：Meier Michael A.R.

  公开号：US20120022276A1

  公开（公告）日：2012-01-26

  The invention relates to a method for producing aldehyde functional compounds by a cross-metathesis reaction of an olefinic compound having at least one hydroxy group and at least one C—C double bond with at least one at least monounsaturated fatty acid or at least one at least monounsaturated fatty acid derivative, in the presence of a metathesis catalyst at a maximum temperature of 180° C. and in the presence of at least one reagent that acts as a protective group-forming compound in relation to the aldehyde group of the aldehyde functional compounds.

  本发明涉及一种方法，通过交叉烯烃反应，在存在最高温度为180℃的交换催化剂和至少一种至少单不饱和脂肪酸或至少一种至少单不饱和脂肪酸衍生物的情况下，将至少具有一个羟基和至少一个C-C双键的烯烃化合物与其反应，形成醛官能团化合物，并在至少存在一种作为保护基形成化合物相对于醛基的试剂的情况下进行。
• POLYOLEFIN RESIN COMPOSITION
  申请人：Adeka Corporation

  公开号：EP2287246A1

  公开（公告）日：2011-02-23

  Disclosed is a polyolefin resin composition which has an excellent transparency even when the polyolefin resin has a high melt flow rate (MFR). The polyolefin resin composition comprises a polyolefin resin having a melt flow rate (MFR) at 230 °C of 20 dg/min or more, (A) a dibenzylidene sorbitol compound represented by the following general formula (1), (wherein n represents an integer of 0 to 2; and R1, R2, R3, R4, and R5 each independently represent a hydrogen atom or the like) and (B) an alkali metal salt compound of organic phosphoric acid ester represented by the following general formula (2), (wherein R6 to R9 each independently represent a hydrogen atom or the like), and wherein the sum of the amount of the component (A) and the component (B) is 0.01 to 1.0 part by mass per 100 parts by mass of the polyolefin resin, and (A)/(B), the ratio (mass ratio) between the component (A) and the component (B), is within a range from 99/1 to 80/20.

  本发明公开了一种聚烯烃树脂组合物，即使聚烯烃树脂的熔体流动速率（MFR）很高，该组合物也具有极佳的透明度。该聚烯烃树脂组合物包括在 230 °C 时熔体流动速率（MFR）为 20 dg/min 或以上的聚烯烃树脂、(A) 由以下通式(1)表示的二亚苄基山梨醇化合物、 (其中 n 代表 0 至 2 的整数；R1、R2、R3、R4 和 R5 各自独立地代表氢原子或类似物）和 (B) 由下式通式（2）代表的有机磷酸酯碱金属盐化合物、 (其中 R6 至 R9 各自独立地代表一个氢原子或类似物），其中组分 (A) 和组分 (B) 的用量总和为每 100 份聚烯烃树脂质量的 0.01 至 1.0 份，组分 (A) 和组分 (B) 的比例（质量比）(A)/(B)在 99/1 至 80/20 的范围内。
• TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY
  申请人：Allergan, Inc.

  公开号：EP3329896A1

  公开（公告）日：2018-06-06

  Ophthalmic products and related methods are described herein. These products include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

  本文描述了眼科产品及相关方法。这些产品包括一种由治疗活性剂组成的稳定组合物，它与液体载体组合物之间有一层隔离层。可以移除隔离物，使两种组合物混合，以提供包含治疗活性剂的眼用可接受液体。